Please login to the form below

Not currently logged in
Email:
Password:

GLP1 agonists

This page shows the latest GLP1 agonists news and features for those working in and with pharma, biotech and healthcare.

EMA: no new safety concerns with GLP-1 diabetes drugs

EMA: no new safety concerns with GLP-1 diabetes drugs

The GLP-1 based therapy class includes both glucagon-like-peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors.

Latest news

  • US charity calls for release of diabetes drug data US charity calls for release of diabetes drug data

    The concerned products comprise GLP-1 agonists, such as Byetta/Bydureon (exenatide) from Amylin/ Bristol Myers Squibb (BMS) and Victoza (liraglutide) from Novo Nordisk, as well as the DPP-4 inhibitors, ... data that reinforced "growing safety concerns"

  • Drug delivery

    Other deals of note were Boehringer Ingelheim's (BI) agreement with Zealand Pharma for rights to its ZP2929 - GLP1 receptor agonists against type 2 diabetes and obesity, further building the ... agonists (T2D and obesity). Development, Commercialisation

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...

Infographics